newsfilter
← Latest News
Earnings Call Transcripts·

10X GENOMICS, INC. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - 10X GENOMICS INC

  • Financial Performance:

    • Revenue & Growth: Single-cell consumables revenue grew mid-single digits sequentially in Q3, defying earlier expectations of a slowdown due to the new Terra platform launch; overall consumable growth remains robust.
    • Profitability & Cash Flow: The company generated approximately $100 million in free cash flow over the last 12 months, indicating a strong P&L and operational efficiency.
    • Instrument Sales: Aimed to sell 50 Terra instruments by year-end, a target management views as ambitious but confident, with plans to ramp production to 50 units per quarter by Q1.
    • Pricing Dynamics: Facing short-term headwinds in average reaction pricing due to the strategic shift to the lower-cost Apex platform, which drives volume but temporarily compresses top-line growth per unit; equilibrium expected within a few quarters.
    • Deferred Revenue: Significant backlog exists for Terra instrument deployments, constrained by manufacturing and field service capacity rather than demand.
  • Guidance and Future Outlook:

    • Short-Term: Expect sequential growth to slow in Q4 as Terra placements begin cannibalizing existing Xenium orders, though a cliff-like drop is not anticipated.
    • Long-Term Goals: Anticipate Terra to become the primary "workhorse" for large-scale spatial biology and foundation model training, potentially outpacing single-cell platforms (Chromium/Perturb-seq) in future high-volume experiments.
    • Product Scalability: Aiming to optimize field service and installation capacity to ensure customer success and immediate consumables pull-through once instruments are installed.
    • Market Expansion: Predicts significant growth driven by AI integration, translational oncology research, and the need for comprehensive multi-target diagnostics for new therapeutic modalities (ADCs, bispecifics).
  • Business Segments and Product Lines:

    • Terra (Spatial): The primary growth driver with "exceeding" customer enthusiasm; initial orders show a diverse mix including customers new to spatial biology, not just existing Xenium users.
    • Xenium: Continues to show resilience with mid-single-digit sequential growth in consumables; viewed as the most prominent and rapidly growing spatial platform in the absence of direct Terra cannibalization.
    • Single-Cell (Chromium/ScRNA-seq): Double-digit reaction growth observed in Flex and Apex kits; Apex strategy focuses on lower price-per-reaction and higher scalability to drive volume.
    • Catalyst Research Services (CRS): Experiencing dramatic demand with over 100 customers signed up; serving as a leading indicator for instrument conversion, with a diverse customer base including academia, biopharma, and even non-traditional sectors like Procter & Gamble.
    • Clinical Initiatives: Establishing a CLIA lab and developing Laboratory Developed Tests (LDTs) to generate clinical evidence for spatial biomarkers, targeting integration with pathology workflows.
  • Market and Competitive Landscape:

    • Competitive Moat: Management asserts a multiple-generation technology lead over competitors, citing the innovative depth of the Terra platform and the convergence of genomics and pathology workflows.
    • Market Trends: AI is a central catalyst, with Terra positioned as the ideal data generation engine for spatial foundation models; demand is shifting toward massive-scale experiments (billions of cells) requiring high-throughput spatial data.
    • Consolidation: Noted industry consolidation (NanoString, Fluent) strengthens the position of remaining leaders; Terra offers a standardized, workflow-integrated solution in a fragmented market.
    • Clinical Demand: Identified a "huge unmet need" in oncology for multiplex spatial diagnostics to guide the selection of new therapies, a use case where traditional IHC is insufficient.
  • Risks and Challenges:

    • Supply Chain & Deployment: Rate-limiting factors include manufacturing capacity for Terra instruments and the availability of field service engineers to install and validate units; site readiness and shipping issues require active management.
    • Product Cannibalization: Anticipated pressure on existing Xenium spatial business and consumables from the introduction of Terra, though early data suggests the transition is smoother than feared.
    • Macro Environment: Academic and government funding remains under pressure, though the company notes the macro environment is currently trending in its favor due to AI investment and biopharma activity.
    • Pricing Pressure: The transition to the Apex platform involves a temporary tension between driving volume and maintaining average reaction pricing.
  • Management Commentary and Tone:

    • Confidence: Management tone is highly confident and optimistic, describing the Terra launch as a "fun" and "exhilarating" story with customer enthusiasm exceeding internal expectations.
    • Strategic Focus: Emphasis on "optimizing for customer success" and ensuring rapid instrument deployment to validate the platform and drive consumable recurring revenue.
    • Innovation: Stressed that Terra is "perfectly built" for the AI era, positioning it as a fundamental shift in how biology is measured at scale.
    • M&A Stance: Prioritizing fundamental business health and cash generation; open to inorganic growth opportunities only if they present a clear strategic rationale.
  • Analyst Questions and Answers:

    • Customer Base Evolution: Clarified that initial Terra orders include a significant portion of customers new to spatial biology, not just existing Xenium owners, broadening the total addressable market.
    • Pull-Through Framework: Reiterated it is too early for specific granular pull-through numbers due to low initial order volume; focus is on prioritizing funded customers to ensure immediate consumables usage.
    • AI & Foundation Models: Differentiated between Perturb-seq (large-scale but embryonic) and spatial data; predicted spatial data from Terra will become the foundation for future large-scale biological models.
    • Clinical Pathway: Detailed the strategy to build clinical cohorts and a CLIA lab to prove the correlation between spatial biomarkers and clinical outcomes, addressing the lack of standardization in the current market.
    • Workflows: Highlighted Terra's advantage in utilizing standard off-the-shelf slides and H&E workflows, reducing friction for pathologists compared to previous complex genomics tools.
  • Other Key Points:

    • Translational Research: A major use case identified is predicting response to therapy and understanding mechanisms of resistance in oncology using new therapeutic modalities.
    • Service Trend: Noted a secular trend toward services where customers prefer buying data/insights rather than capital equipment, validating the expansion of CRS.
    • Technology Integration: The convergence of AI inference capabilities with spatial data generation is seen as the key to condensing complex molecular data into actionable clinical decisions.
    • Instrument Demand: The internal competition between shipping instruments to customers versus using them for internal Catalyst projects was noted as the "most contentious issue" in the company due to high demand.
Company
10X GENOMICS INC
Keywords
10X GENOMICS INC